Erythropoietin in cancer patients

Annual Review of Medicine

Volumn 60, Issue , 2009, Pages 181-192

  Glaspy, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Darbepoetin; Epoetin; Erythropoietin receptor; Hypoxia; Safety; Survival; Thrombosis

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL HYPOXIA; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; HEAD AND NECK CANCER; HUMAN; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; VEIN THROMBOSIS;

ANEMIA; CELL HYPOXIA; DISEASE PROGRESSION; DRUG RESISTANCE; ERYTHROPOIETIN; HEMATINICS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 67650717647     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.60.050307.110718     Document Type: Review

References (70)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. 2004. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40:2293-306
2. Ludwig H. 2004. rHuEPO and treatment outcomes: the preclinical experience. Oncologist 5:48-54
3. Caro JJ, Salas M,Ward A, et al. 2001. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214-21
4. Knight K,Wade S, Balducci L. 2004. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am. J. Med. 5:11S-26S
5. Ganz T. 2003. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783-88
6. Rivera S, Liu L, Nemeth E, et al. 2005. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 105:1797-802
7. Miller CB, Jones RJ, Piantadosi S, et al. 1990. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 322:1689-92
8. Bohlius J, Wilson J, Seidenfeld J, et al. 2006. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 98:708-14
9. Bohlius J, Langensiepen S, Schwarzer G, et al. 2004. Erythropoietin for patients with malignant disease. Cochrane Database Syst. Rev. 3
10. Bohlius J, Wilson J, Seidenfeld J, et al. 2006. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. 3:CD003407
11. Smith RE, Aapro MS, Ludwig H, et al. 2008. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 26:1040-50
12. Curt GA, Breitbart W, Cella D, et al. 2000. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353-60
13. Glaspy J, Bukowski R, Steinberg D, et al. 1997. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 15:1218-34
14. Cella D, Kallich J, McDermott A, et al. 2004. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann. Oncol. 15:979-86
15. Littlewood TJ, Bajetta E, Nortier JW, et al. 2001. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, doubleblind, placebo-controlled trial. J. Clin. Oncol. 19:2865-74
16. Cella D, Zagari MJ, Vandoros C, et al. 2003. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J. Clin. Oncol. 21:366-73
17. Berndt E, Kallich J, McDermott A, et al. 2005. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 23:505-14
18. Lyman GH, Berndt ER, Kallich JD, et al. 2005. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 8:149-56
19. Ross SD, Fahrbach K, Frame D, et al. 2003. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin. Ther. 25:1786-805
20. Glaspy JA. 2005. The development of erythropoietic agents in oncology. Expert Opin. Emerg. Drugs 10:553-67
21. Auerbach M, Ballard H, Trout JR, et al. 2004. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22:1301-7
22. Henry DH, Dahl NV, Auerbach M, et al. 2007. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231-42
23. Hedenus M, Birgegard G, Nasman P, et al. 2007. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21:627-32
24. Bastit L, Vandebroek A, Altintas S, et al. 2008. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 26:1611-18
25. Pedrazzoli P, Farris A, Del Prete S, et al. 2008. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J. Clin. Oncol. 26:1619-25
26. Chertow GM, Mason PD, Vaage-Nilsen O, et al. 2006. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 21:378-82
27. Auerbach M, Ballard H, Glaspy J. 2007. Clinical update: intravenous iron for anaemia. Lancet 369:1502-4
28. Jelkmann W. 2004. Molecular biology of erythropoietin. Intern. Med. 43:649-59
29. Manalo DJ, Rowan A, Lavoie T, et al. 2005. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659-69
30. Zhong H, De Marzo AM, Laughner E, et al. 1999. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830-35
31. Semenza GL. 2000. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35:71-103
32. Semenza GL. 2004. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5:405-6
33. Teicher BA, Holden SA, al-Achi A, et al. 1990. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 50:3339-44
34. Dunst J, Kuhnt T, Strauss HG, et al. 2003. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int. J. Radiat. Oncol. Biol. Phys. 56:778-87
35. Brizel DM, Dodge RK, Clough RW, et al. 1999. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53:113-17
36. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. 2005. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23:5960-72
37. Henke M, Laszig R, Rube C, et al. 2003. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-60
38. Overgaard J, Hoff C, Sand Hansen H, et al. 2007. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp® ) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA. Eur. J. Cancer 5:7, Abstr. 6LB
39. Aapro M, Leonard RC, Barnadas A, et al. 2008. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J. Clin. Oncol. 26:592-98
40. Vaupel P, Thews O, Mayer A, et al. 2002. Oxygenation status of gynecologic tumors: What is the optimal hemoglobin level? Strahlenther. Onkol. 178:727-31
41. Zhao W, Kitidis C, Fleming MD, et al. 2006. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 107:907-15
42. Anagnostou A, Lee ES, Kessimian N, et al. 1990. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 87:5978-82
43. Ribatti D, Presta M, Vacca A, et al. 1999. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-36
44. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. 2000. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95:2983-89
45. Hardee ME, Cao Y, Fu P, et al. 2007. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2:e549
46. Acs G, Acs P, Beckwith SM, et al. 2001. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61:3561-65
47. Arcasoy MO, Amin K, Chou SC, et al. 2005. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin. Cancer Res. 11:20-27
48. Elliott S, Busse L, Bass MB, et al. 2006. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107:1892-95
49. Brown WM, Maxwell P, Graham AN, et al. 2007. Erythropoietin receptor expression in nonsmall cell lung carcinoma: a question of antibody specificity. Stem Cells 25:718-22
50. Sinclair AM, Rogers N, Busse L, et al. 2008. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br. J. Cancer 98:1059-67
51. Sinclair AM, Todd MD, Forsythe K, et al. 2007. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110:477-88
52. Acs G, Chen M, Xu X, et al. 2004. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett. 214:243-51
53. Hardee ME, Arcasoy MO, Blackwell KL, et al. 2006. Erythropoietin biology in cancer. Clin. Cancer Res. 12:332-39
54. Solar P, Feldman L, Jeong JY, et al. 2008. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int. J. Cancer 122:281-88
55. Casadevall N, Nataf J, Viron B, et al. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-75
56. Bennett CL, Luminari S, Nissenson AR, et al. 2004. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351:1403-8
57. Akl EA, Kamath G, Kim SY, et al. 2007. Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a Cochrane systematic review. J. Exp. Clin. Cancer Res. 26:175-84
58. Akl EA, van Doormaal FF, Barba M, et al. 2007. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst. Rev. 3:CD006652
59. FDA. 2008. Briefing document. http://wwwfdagov/ohrms/dockets/ ac/08/briefing/2008-4345b2-01-FDApdf
60. Amgen. 2008. Briefing document. http://wwwfdagov/ohrms/dockets/ ac/08/briefing/2008-4345b2-05-AMGENpdf
61. Amgen. 2007. Supplement to briefing document. http://wwwfdagov/ ohrms/dockets/ac/07/briefing/2007-4301b2-01-01-AMGEN-odac-supplement-2007pdf
62. Machtay M, Pajak TF, Suntharalingam M, et al. 2007. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int. J. Radiat. Oncol. Biol. Phys. 69:1008-17
63. Chang J, Couture F, Young S, et al. 2005. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol. 23:2597-605
64. Wright JR, Ung YC, Julian JA, et al. 2007. Randomized, double-blind, placebo-controlled trial of erythropoietin in nonsmall-cell lung cancer with disease-related anemia. J. Clin. Oncol. 25:1027-32
65. Vansteenkiste J, Pirker R, Massuti B, et al. 2002. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl. Cancer Inst. 94:1211-20
66. Amgen. 2007. Briefing document. http://wwwfdagov/ohrms/dockets/ ac/07/briefing/2007-4301b2-01-01-Amgenpdf
67. Seidenfeld J, Piper M, Bohlius J, et al. 2006. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026
68. Charu V, Belani CP, Gill AN, et al. 2007. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist 12:727-37
69. Crawford J, Robert F, Perry MC, et al. 2007. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with nonsmall cell lung cancer scheduled to receive first-line chemotherapy. J. Thorac. Oncol. 2:210-20
70. Lyman GH, Glaspy J. 2006. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 106:223-33